大黄素对T淋巴细胞白血病Jurkat、Molt-4细胞株增殖、凋亡的影响及其机制的初步研究
|
摘要
目的①研究中药大黄素对人T淋巴细胞白血病Jurkat、Molt-4细胞株增殖、凋亡的影响。②观察大黄素对Jurkat、Molt-4细胞增殖、凋亡相关基因及蛋白表达水平的影响,探讨其作用机制。③观察大黄素对Jurkat、Molt-4细胞作用后PI3K/Akt信号转导通路中蛋白表达的变化。
方法应用MTT法绘制细胞生长曲线、细胞克隆形成实验观察大黄素对Jurkat、Molt-4细胞增殖的影响; DNA片段化分析、Annexin V/PI双染流式细胞检测、末端缺口原位标记(TUNEL)法及DNA倍体分析检测大黄素对细胞凋亡的影响;蛋白印迹法(Western-Blot)检测c-myc、bcl-2、pro-与cleaved caspase-3、pro-caspase-8、pro-caspase-9、PARP蛋白以及PI3K/Akt信号转导通路中蛋白表达水平的变化。
结果(1)细胞生长曲线结果显示大黄素能明显抑制Jurkat、Molt-4细胞增殖,48h半数抑制浓度(IC50)分别为20.7μmol·L-1和25.1μmol·L-1。DNA片段化、DNA倍体分析亚二倍体峰、TUNEL法凋亡细胞的检出及Annexin V/PI双染流式细胞检测等证实大黄素能有效诱导Jurkat细胞凋亡,细胞凋亡率在一定的药物浓度范围内与药物作用浓度和作用时间呈正相关。DNA片段化的检出同样表明大黄素可诱导Molt-4细胞凋亡。(2)80μmol·L-1大黄素作用Jurkat细胞不同时间和不同浓度大黄素作用Jurkat细胞后,c-myc、bcl-2、hTERT、pro-caspase-3、pro-caspase-8、procaspase-9蛋白表达下调,同时cleaved caspase-3和cleaved PARP蛋白的表达上调,并呈量效与时效关系。相同浓度大黄素作用Molt-4细胞后,bcl-2、c-myc、hTERT与procaspase-3蛋白表达下调。(3)大黄素可作用于Jurkat、Molt-4细胞Akt信号通路,下调Jurkat细胞中p-Akt、IκB-α、p-IκB-α、p-NF-κB、mTOR、p-mTOR、GSK-3β、p-GSK-3β、MAPK和p-MAPK的表达,而Akt、NF-κB表达变化不明显,Bad表达上调;大黄素还下调Molt-4细胞中Akt、p-AKT、m-TOR、p-mTOR蛋白表达。
结论(1)大黄素能有效抑制Jurkat、Molt-4细胞增殖,诱导其凋亡,在一定浓度范围内呈剂量时间效应关系。大黄素可能是通过下调c-myc、bcl-2、hTERT及caspase家族的蛋白表达诱导细胞凋亡。(2) Akt信号通路参与了大黄素抑制Jurkat、Molt-4细胞增殖、诱导凋亡的过程。
【Objective】To investigate the effects of Chinese traditional medicine Emodin on proliferation and apoptosis in T lymphocytic leukemic cell line Jurkat and Molt-4 and to explore the mechanisms of the effects by measuring the expression of proliferation and apoptosis related proteins as well as the expression of PI3K/AKT signaling pathway proteins.
【Methods】Cell proliferation inhibition was detected by MTT assay. Cell apoptosis was measured by DNA ladder, Annexin V/PI double staining analysis, terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling(TUNEL) assay and cell cycle analysis. The expressions of apoptosis related proteins, caspase family members and PI3K/AKT signaling pathway proteins were determined by Western Blot.【Results】(1) Emodin inhibited proliferation in Jurkat and Molt-4 cells, with the IC50 in 48h at 20.7μmol·L-1 and 25.1μmol·L-1, respectively. Cell apoptosis was observed with both time and dose dependent manner in Jurkat cells and also observed in Molt-4 cells by the detection of DNA fragments. (2) In Jurkat cells, the expressions c-myc, hTERT and Bcl-2 were explored to be down-regulated after the treatment of Emodin in a time dependent manner. Caspase-3, PARP were both activated, while the expressions of procaspase-8 and 9 both decreased. In Molt-4 cells, c-myc, bcl-2 were down-regulated and caspase-3, PARP were both activated after the treatment of Emodin. (3)Emodin have effects on PI3K/AKT signaling pathway in both Jurkat and Molt-4 cells, with the down-regulation of p-Akt、IκB-α、p-IκB-α、 p-NF-κB、mTOR、p-mTOR、GSK-3β、p-GSK-3β、MAPK and p-MAPK in Jurkat cells and Akt、p-Akt、mTOR and p-mTOR in Molt-4 cells, while the expression of Akt and NF-κB showed no significant change and the expression of Bad in creased in Jurkat cells.
【Conclusion】(1)Emodin could remarkbly inhibit proliferation and induce apoptosis in Jurkat and Molt-4 cells, and the down-regulation of bcl-2、c-myc、hTERT and caspase family members may have contributed to the apoptosis process.(2)PI-3K/Akt signaling pathway may have involved in the apoptosis of Jurkat and Molt-4 cells after treatment with Emodin.
方法应用MTT法绘制细胞生长曲线、细胞克隆形成实验观察大黄素对Jurkat、Molt-4细胞增殖的影响; DNA片段化分析、Annexin V/PI双染流式细胞检测、末端缺口原位标记(TUNEL)法及DNA倍体分析检测大黄素对细胞凋亡的影响;蛋白印迹法(Western-Blot)检测c-myc、bcl-2、pro-与cleaved caspase-3、pro-caspase-8、pro-caspase-9、PARP蛋白以及PI3K/Akt信号转导通路中蛋白表达水平的变化。
结果(1)细胞生长曲线结果显示大黄素能明显抑制Jurkat、Molt-4细胞增殖,48h半数抑制浓度(IC50)分别为20.7μmol·L-1和25.1μmol·L-1。DNA片段化、DNA倍体分析亚二倍体峰、TUNEL法凋亡细胞的检出及Annexin V/PI双染流式细胞检测等证实大黄素能有效诱导Jurkat细胞凋亡,细胞凋亡率在一定的药物浓度范围内与药物作用浓度和作用时间呈正相关。DNA片段化的检出同样表明大黄素可诱导Molt-4细胞凋亡。(2)80μmol·L-1大黄素作用Jurkat细胞不同时间和不同浓度大黄素作用Jurkat细胞后,c-myc、bcl-2、hTERT、pro-caspase-3、pro-caspase-8、procaspase-9蛋白表达下调,同时cleaved caspase-3和cleaved PARP蛋白的表达上调,并呈量效与时效关系。相同浓度大黄素作用Molt-4细胞后,bcl-2、c-myc、hTERT与procaspase-3蛋白表达下调。(3)大黄素可作用于Jurkat、Molt-4细胞Akt信号通路,下调Jurkat细胞中p-Akt、IκB-α、p-IκB-α、p-NF-κB、mTOR、p-mTOR、GSK-3β、p-GSK-3β、MAPK和p-MAPK的表达,而Akt、NF-κB表达变化不明显,Bad表达上调;大黄素还下调Molt-4细胞中Akt、p-AKT、m-TOR、p-mTOR蛋白表达。
结论(1)大黄素能有效抑制Jurkat、Molt-4细胞增殖,诱导其凋亡,在一定浓度范围内呈剂量时间效应关系。大黄素可能是通过下调c-myc、bcl-2、hTERT及caspase家族的蛋白表达诱导细胞凋亡。(2) Akt信号通路参与了大黄素抑制Jurkat、Molt-4细胞增殖、诱导凋亡的过程。
【Objective】To investigate the effects of Chinese traditional medicine Emodin on proliferation and apoptosis in T lymphocytic leukemic cell line Jurkat and Molt-4 and to explore the mechanisms of the effects by measuring the expression of proliferation and apoptosis related proteins as well as the expression of PI3K/AKT signaling pathway proteins.
【Methods】Cell proliferation inhibition was detected by MTT assay. Cell apoptosis was measured by DNA ladder, Annexin V/PI double staining analysis, terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling(TUNEL) assay and cell cycle analysis. The expressions of apoptosis related proteins, caspase family members and PI3K/AKT signaling pathway proteins were determined by Western Blot.【Results】(1) Emodin inhibited proliferation in Jurkat and Molt-4 cells, with the IC50 in 48h at 20.7μmol·L-1 and 25.1μmol·L-1, respectively. Cell apoptosis was observed with both time and dose dependent manner in Jurkat cells and also observed in Molt-4 cells by the detection of DNA fragments. (2) In Jurkat cells, the expressions c-myc, hTERT and Bcl-2 were explored to be down-regulated after the treatment of Emodin in a time dependent manner. Caspase-3, PARP were both activated, while the expressions of procaspase-8 and 9 both decreased. In Molt-4 cells, c-myc, bcl-2 were down-regulated and caspase-3, PARP were both activated after the treatment of Emodin. (3)Emodin have effects on PI3K/AKT signaling pathway in both Jurkat and Molt-4 cells, with the down-regulation of p-Akt、IκB-α、p-IκB-α、 p-NF-κB、mTOR、p-mTOR、GSK-3β、p-GSK-3β、MAPK and p-MAPK in Jurkat cells and Akt、p-Akt、mTOR and p-mTOR in Molt-4 cells, while the expression of Akt and NF-κB showed no significant change and the expression of Bad in creased in Jurkat cells.
【Conclusion】(1)Emodin could remarkbly inhibit proliferation and induce apoptosis in Jurkat and Molt-4 cells, and the down-regulation of bcl-2、c-myc、hTERT and caspase family members may have contributed to the apoptosis process.(2)PI-3K/Akt signaling pathway may have involved in the apoptosis of Jurkat and Molt-4 cells after treatment with Emodin.
引文
[1]陈子,吴秋玲,陈燕等.白桦脂酸对Jurkat白血病细胞增殖和凋亡的影响.中华肿瘤杂志,2008; 30: 588-592
[2]刘兵城,肖志坚.甲异靛对Jurkat细胞AKT信号通路的影响及其在细胞凋亡中作用的研究.临床血液学杂志,2008;21: 255-259
[3] Lu Y, Zhang J, Qian J, et al. The effect of emodin on VEGF receptors in human colon cancer cells. Cancer Biother Radiopharm. 2008; 23: 222-228
[4] Cai J, Razzak A, Hering J, et al. Feasibility evaluation of emodin (rhubarb extract) as an inhibitor of pancreatic cancer cell proliferation in vitro. J Parenter Enteral Nutr. 2008 Mar-Apr;32:190-196.
[5] Fu ZY, Han JX, Huang HY. Effects of emodin on gene expression profile in small cell lung cancer NCI-H446 cells. Chin Med J (Engl). 2007; 120:1710-1715
[6]Huang Z, Chen G, Shi P, et al. Emodin-induced apoptosis in human breast cancer BCap-37 cells through the mitochondrial signaling pathway. Arch Pharm Res. 2008; 31:742-748. [47Kuo PL, Hsu YL, Ng LT, et al. Rhein inhibits the growth and induces the apoptosis in HepG2 cells. Planta Med, 2004; 70: 12-16
[8]南菁,秦云霞,刘晶等.芦荟大黄素对人胃癌细胞HGC-27增殖周期及凋亡的影响.现代肿瘤医学, 2008; 16: 919-921
[9]王青,周婷,周联等.大黄素对HT-29细胞IL-8分泌及NF-κB活化的影响.中国药理学通报, 2007; 21: 1541-1555
[10] Chen YC, Shen SC, Lee WR,et al. Emodin induces apoptosis in human promyeloleukemic HL-60 cells accompanied by activation of caspase 3 cascade but independent of reactive oxygen species production. Biochem Pharmacol, 2002; 64:1713-1724
[12]毛咏秋,李喜荣,雷松.几种抗肿瘤药物诱导Jurkat细胞凋亡的研究.中国实验血液学杂志, 2006; 14: 681-685
[12] Buenz EJ. Aloin induces apoptosis in Jurkat cells. Toxicol In Vitro. 2008; 22:422-429.
[13]胡芬,孙文武,宋志成等.芦荟大黄素对Jurkat T细胞增殖和凋亡的作用及机制.中草药, 2008; 39: 231-236
[14]苗新宇,洪振亚,易莉莎等.曲古抑菌素A诱导MOLT-4细胞凋亡的机制.华中科技大学学报(医学版),2007;36:344-347
[15] NAGATA S. Apoptotic DNA fragmentation. Exp Cell Res, 2000; 10: 12-18
[16]陈英玉,郑合勇,胡建达等.大黄素抑制HL-60/ADR耐药细胞增殖和诱导凋亡的作用.中国实验血液学杂志,2007; 15: 955-960
[17]连晓岚,胡建达,郑志宏等.大黄素诱导白血病U937细胞凋亡及机制初探.中国药理学通报,2007; 23: 1312-1316
[18]王一飞,李灼日.原癌基因c-myc与恶性肿瘤.医学临床研究,2008; 25: 1698-1700
[19] Guo J, Xiao B, Liu Q,et al. Suppression of C-myc expression associates with anti-proliferation of aloe-emodin on gastric cancer cells. Cancer Invest. 2008; 26: 369-374.
[20] Preisler HD, Haza A, Larson R, et al. Protooncogene expression and the clinical characteristics of acute nonlymphocytic leukemia: a leukemia intergroup pilot study. Blood, 1989; 73: 255-262
[21]黄绿叶,胡建达,陈鑫基等. C-myc在大黄素抑制HL-60细胞增殖及诱导凋亡中的作用.中华血液学杂志,2005; 26: 348-351
[22] Pallini R, Pierconti F, Falchetti ML, et al. Evidence for telomerase involvement in the angiogenesis of astro-cytic tumors expression of human telomerase reverse to anscriptase messenger RNA by vascular endothial cells. J Neureseug, 2001; 94: 961-971
[23]Greenberg RA,O’Hagan RC, Deng H, et al. Tolemerase reverse transcriptase gene is a direct target of c-myc but is not functionally equivalent in cellular transformation. Oncogene, 1999, 18:1219-1226
[24] Petros AM, Olejniczak ET, Fesik SW, et al. Structural biology of the Bcl-2 family of proteins. Biochem Biophys Acta, 2004; 1644: 83-94
[25] Orrenius S. Mitochondrial regulation of apoptotic cell death. Toxical Lett, 2004; 149: 19-23
[26]Huang Z. Bcl-2 family proteins as targets for anticancer drug design. Oncogene, 2000; 19: 6627-6631
[27]Peng ZF, Lan LX, Zhao F, et al. A novel thioredoxin reductase inhibitor inhibits cell growth and induces apoptosis in HL-60 and K562 cells. Zhejiang Univ Sci B, 2008, 9:16-21.
[28]李小明,孙志贤.细胞凋亡中的关键蛋白酶caspase-3.国外医学分子生物学分册, 1999; 21: 6-9
[29] Budihardjo I, Oliver H, Lutter M, et al. Biochemical pathways of caspase activation during apoptosis. Annau Rev Cell Dev Biol, 1999; 15: 269-290
[30] Saikumar P, Dong Z, Mikhailov V, et al. Apoptosis: definition, mechanism and relevance to disease. Am J Med, 1999; 107: 489-506
[31]李静岩. Caspase-3与肿瘤关系的研究.医学综述, 2005; 11: 430-2
[32] Su YT, Cheng HL, Shyue SK, et al. Emodin induces apoptosis in human lung adenocarcinoma cells through a reactive oxygen species-dependent mitochondrial signaling pathway. Biochem Pharmacol, 2005, 70: 229-241
[33] Wang C, Wu X, Chen M,et al. Emodin induces apoptosis through caspase 3-dependent pathway in HK-2 cells. Toxicology. 2007, 231:120-128
[34] A Ivana Scovassa, Marc Diederich. Modulation of Poly (ADP-ribosylation) in apoptotic cells. Biochemical pharmacology, 2004; 5: 1041-1047.
[35] Yang J, Liu X, Bhalla K, et al. Prevention of apoptosis by bcl-2: release of cytochrom C from mitochondria blocked. Science, 1997; 275: 1129-1132
[36] Kangas A, Nicholson DW. Involvement of CPP32/caspase-3 in c-myc-induced apoptosis. Oncogene, 1998; 16: 387-398
[37]郑合勇,胡建达,郑志宏等.大黄素可能通过抑制AKT信号通路诱导HL-60细胞凋亡.药学学报, 2007; 42:1142-6.
[38] Osaki M, Oshimura M, Ito H. PI-3K/AKT pathway: its functions and alterations in human cancer. Apoptosis, 2004; 9: 667-76
[39] Song G, Ouyang G L, Bao S D. The activation of AKT/PKB signaling pathway and cell survival. J Cell Mol Med, 2005; 9: 59-71
[40] Kubota Y, Ohnishi H, Kitanaka A, et al. Constitutive activation of PI3K isinvolved in the spontaneous proliferation of primary acute myeloid leukemia cells: direct evidence of PI3K activation. Leukemia, 2004; 18: 1438-1340
[41]王东海,王建祥. PI-3K/AKT信号通路异常与白血病.国际输血及血液学杂志. 2006; 29: 21-25
[42] Hussain AR, AL-Rasheed M, Manogaran PS, et al. Curcumin induces apoptosis via inhibition of PI3-kinase/AKT pathway in acute T cell leukemias. Apoptosis, 2006; 11: 245-254
[43]Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev, 2004; 18: 1926-1945
[44]Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell, 2000; 103: 253-262
[45] Xu Q, Simpson SE, Schalla TJ, et al. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood, 2003; 102: 972-980
[46] Recher C, Beyne-Rauzy O, Demur C, et al. Antileukemic activity or fapamycin in acute myeloid leukemia. Blood, 2005; 105: 2527-2534
[47] Li P, Nijhawan D, Srinivasula SM, et al. Cytochrome C and dATP-dependent formation of Apaf1/caspase-9 complex initiates apoptotic protease cascade. Cell, 1997; 91: 479
[48] Peso LM, Gonzales-Garcia C, Page R, et al. Interleukin-3-induced phosphorylation of Bad through the protein kinase AKT. Science, 1997, 278: 687-689
[49]陈丹英,舒红兵,翟中和等.细胞凋亡与NF-κB激活的信号传导研究.北京大学学报(自然科学版), 2006; 42: 141-146
[50] Madrid LV, Mayo MW, Reuther JY, et al. Akt stimulates the transactivation potential of the Rel/p65 subunit of NF kappa B through utilization of the I kappa B kinase and activation of the mitogen activated protein kinase p38. Biol Chem, 2001; 276: 18934-18940
[51] Cross DA, Culbert AA, Chalmers KA, et al. Selective small-molecule inhibitors of glycogen synthase kinase 23 activity protect primary neurons from death. J Neurochem, 2001; 77: 94-102
[52] Rane MJ, Coxon PY, Powell DW, et al. P38 kinase-dependent MAPK APK-2activation functions as 3-phosphoinositide-dependent kinase-2 for AKT in human neutrophils. J Biol Chem, 2001; 276: 3517-3523
[53] Stellman LS, Pohnert SC, Shelton JG, et al. JAK/STAT, Raf/MEK/ERK, PI3K/AKT and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia, 18: 189-218
1.陈赛娟,陈丽娟,周光飚.白血病基因产物靶向治疗的基础和临床研究.中国实验血液学杂志,2005;13:1-8
2.Kantarjian HM, Cortes JE, O Brien S, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase myeloid leukemia after failure of intereron alpha. Blood, 2004, 104:1979-1988
3.Kaufmann SH, Steensma DP. On the TRAIL of a new therapy for leukemia. Leukemia, 2005, 19:2195-2202
4.郝坡,刘北忠.白血病分子靶向治疗研究进展.现代肿瘤医学. 2007, 15: 719-722
5.金洁.急性髓系白血病的治疗策略.国际输血及血液学杂志. 2007, 30: 198-203
6.Deiniger M W, Goldman JM, Melo JV, et al. The molecular biology of chronic myeloid leukemia. Blood. 2000, 96: 3343-3356
7.Sciandrello G, Garadonna F, Mauro M, et al. Arsenic induced DNA hypomethylation affects chromosomed instability in mammalian cells. Carcinogenesis, 2004, 25: 413-417
8.Lopes deMenezes DE, Jing Peng, Garrett EN, et all. Chir258: a potent inhibitor of FLT-3 kinase in experimental tumor xenograft models of human acute myelogenous leumemia. Clin Cancer Res, 2005, 11: 5281-5291
9.邓扬嘉,娄世锋.白血病靶向治疗新进展.医学综述, 2006,12:116-119
10. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antianglogenesis, involvement of vascular endothelial growh fator. Nat Med, 2002, 8: 128-135
11. Sternberg DW, Gilliland DG. The role of signal transducer and activator of transcription factors in leukemogenesis. J Clin Oncol, 2004, 22: 361-371
12.王东海,王建祥. PI-3K/AKT信号通路异常与白血病.国际输血及血液学杂志,2006, 29: 21-23
13. Loh ML, Vattikuti S, Schubbert S, et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood, 2004, 103: 2325-2331
14.姚尔固.白血病的靶向治疗.白血病·淋巴瘤,2005, 14: 41-43
15. Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously therapy chronic lymphocytic leukemia. Clinical Oncology, 1997, 15: 1567.
16. Jurcic JG, DeBlasio A, Dumont L, et al. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute myeloid leudemia. Clin Cancer Res, 2000, 6: 372-380.
17. Leopold LH, Berger MS, Feingold J. Acute and long-term toxicties associated with gemtuzumab ozogamicin (Mylotarg) therapy of acute myeloid leukemia. Clin Lymphoma, 2002, 2: 21-34.
18. Abken H, Hombach A, Reinhold U, et al. Can combined cell and antibody based immunotherapy outsmart tumor cell. Immunal today, 1998, 19: 2.
19.崔福德..药剂学.北京:人民卫生出版社. 2003
20.杨东光.慢性粒细胞白血病靶向治疗药物实验研究进展.中国实验血液学杂志, 2007, 15: 211-214
21.Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell, 2005; 7:129-141
22. Christman JK. 5-Azacytidine and 5-aza-2-deoxycytidine as inhibitors of DNA methylation; mechanistic studies and their implications for cancer therapy. Oncogene, 2002, 21:5483-5495.
23.Voorhees PM, Dees EC, o’Neil B, et al. The proteasome as a target for cancer therapy, Clinical Cancer, 2003, 9: 6316-6325
[2]刘兵城,肖志坚.甲异靛对Jurkat细胞AKT信号通路的影响及其在细胞凋亡中作用的研究.临床血液学杂志,2008;21: 255-259
[3] Lu Y, Zhang J, Qian J, et al. The effect of emodin on VEGF receptors in human colon cancer cells. Cancer Biother Radiopharm. 2008; 23: 222-228
[4] Cai J, Razzak A, Hering J, et al. Feasibility evaluation of emodin (rhubarb extract) as an inhibitor of pancreatic cancer cell proliferation in vitro. J Parenter Enteral Nutr. 2008 Mar-Apr;32:190-196.
[5] Fu ZY, Han JX, Huang HY. Effects of emodin on gene expression profile in small cell lung cancer NCI-H446 cells. Chin Med J (Engl). 2007; 120:1710-1715
[6]Huang Z, Chen G, Shi P, et al. Emodin-induced apoptosis in human breast cancer BCap-37 cells through the mitochondrial signaling pathway. Arch Pharm Res. 2008; 31:742-748. [47Kuo PL, Hsu YL, Ng LT, et al. Rhein inhibits the growth and induces the apoptosis in HepG2 cells. Planta Med, 2004; 70: 12-16
[8]南菁,秦云霞,刘晶等.芦荟大黄素对人胃癌细胞HGC-27增殖周期及凋亡的影响.现代肿瘤医学, 2008; 16: 919-921
[9]王青,周婷,周联等.大黄素对HT-29细胞IL-8分泌及NF-κB活化的影响.中国药理学通报, 2007; 21: 1541-1555
[10] Chen YC, Shen SC, Lee WR,et al. Emodin induces apoptosis in human promyeloleukemic HL-60 cells accompanied by activation of caspase 3 cascade but independent of reactive oxygen species production. Biochem Pharmacol, 2002; 64:1713-1724
[12]毛咏秋,李喜荣,雷松.几种抗肿瘤药物诱导Jurkat细胞凋亡的研究.中国实验血液学杂志, 2006; 14: 681-685
[12] Buenz EJ. Aloin induces apoptosis in Jurkat cells. Toxicol In Vitro. 2008; 22:422-429.
[13]胡芬,孙文武,宋志成等.芦荟大黄素对Jurkat T细胞增殖和凋亡的作用及机制.中草药, 2008; 39: 231-236
[14]苗新宇,洪振亚,易莉莎等.曲古抑菌素A诱导MOLT-4细胞凋亡的机制.华中科技大学学报(医学版),2007;36:344-347
[15] NAGATA S. Apoptotic DNA fragmentation. Exp Cell Res, 2000; 10: 12-18
[16]陈英玉,郑合勇,胡建达等.大黄素抑制HL-60/ADR耐药细胞增殖和诱导凋亡的作用.中国实验血液学杂志,2007; 15: 955-960
[17]连晓岚,胡建达,郑志宏等.大黄素诱导白血病U937细胞凋亡及机制初探.中国药理学通报,2007; 23: 1312-1316
[18]王一飞,李灼日.原癌基因c-myc与恶性肿瘤.医学临床研究,2008; 25: 1698-1700
[19] Guo J, Xiao B, Liu Q,et al. Suppression of C-myc expression associates with anti-proliferation of aloe-emodin on gastric cancer cells. Cancer Invest. 2008; 26: 369-374.
[20] Preisler HD, Haza A, Larson R, et al. Protooncogene expression and the clinical characteristics of acute nonlymphocytic leukemia: a leukemia intergroup pilot study. Blood, 1989; 73: 255-262
[21]黄绿叶,胡建达,陈鑫基等. C-myc在大黄素抑制HL-60细胞增殖及诱导凋亡中的作用.中华血液学杂志,2005; 26: 348-351
[22] Pallini R, Pierconti F, Falchetti ML, et al. Evidence for telomerase involvement in the angiogenesis of astro-cytic tumors expression of human telomerase reverse to anscriptase messenger RNA by vascular endothial cells. J Neureseug, 2001; 94: 961-971
[23]Greenberg RA,O’Hagan RC, Deng H, et al. Tolemerase reverse transcriptase gene is a direct target of c-myc but is not functionally equivalent in cellular transformation. Oncogene, 1999, 18:1219-1226
[24] Petros AM, Olejniczak ET, Fesik SW, et al. Structural biology of the Bcl-2 family of proteins. Biochem Biophys Acta, 2004; 1644: 83-94
[25] Orrenius S. Mitochondrial regulation of apoptotic cell death. Toxical Lett, 2004; 149: 19-23
[26]Huang Z. Bcl-2 family proteins as targets for anticancer drug design. Oncogene, 2000; 19: 6627-6631
[27]Peng ZF, Lan LX, Zhao F, et al. A novel thioredoxin reductase inhibitor inhibits cell growth and induces apoptosis in HL-60 and K562 cells. Zhejiang Univ Sci B, 2008, 9:16-21.
[28]李小明,孙志贤.细胞凋亡中的关键蛋白酶caspase-3.国外医学分子生物学分册, 1999; 21: 6-9
[29] Budihardjo I, Oliver H, Lutter M, et al. Biochemical pathways of caspase activation during apoptosis. Annau Rev Cell Dev Biol, 1999; 15: 269-290
[30] Saikumar P, Dong Z, Mikhailov V, et al. Apoptosis: definition, mechanism and relevance to disease. Am J Med, 1999; 107: 489-506
[31]李静岩. Caspase-3与肿瘤关系的研究.医学综述, 2005; 11: 430-2
[32] Su YT, Cheng HL, Shyue SK, et al. Emodin induces apoptosis in human lung adenocarcinoma cells through a reactive oxygen species-dependent mitochondrial signaling pathway. Biochem Pharmacol, 2005, 70: 229-241
[33] Wang C, Wu X, Chen M,et al. Emodin induces apoptosis through caspase 3-dependent pathway in HK-2 cells. Toxicology. 2007, 231:120-128
[34] A Ivana Scovassa, Marc Diederich. Modulation of Poly (ADP-ribosylation) in apoptotic cells. Biochemical pharmacology, 2004; 5: 1041-1047.
[35] Yang J, Liu X, Bhalla K, et al. Prevention of apoptosis by bcl-2: release of cytochrom C from mitochondria blocked. Science, 1997; 275: 1129-1132
[36] Kangas A, Nicholson DW. Involvement of CPP32/caspase-3 in c-myc-induced apoptosis. Oncogene, 1998; 16: 387-398
[37]郑合勇,胡建达,郑志宏等.大黄素可能通过抑制AKT信号通路诱导HL-60细胞凋亡.药学学报, 2007; 42:1142-6.
[38] Osaki M, Oshimura M, Ito H. PI-3K/AKT pathway: its functions and alterations in human cancer. Apoptosis, 2004; 9: 667-76
[39] Song G, Ouyang G L, Bao S D. The activation of AKT/PKB signaling pathway and cell survival. J Cell Mol Med, 2005; 9: 59-71
[40] Kubota Y, Ohnishi H, Kitanaka A, et al. Constitutive activation of PI3K isinvolved in the spontaneous proliferation of primary acute myeloid leukemia cells: direct evidence of PI3K activation. Leukemia, 2004; 18: 1438-1340
[41]王东海,王建祥. PI-3K/AKT信号通路异常与白血病.国际输血及血液学杂志. 2006; 29: 21-25
[42] Hussain AR, AL-Rasheed M, Manogaran PS, et al. Curcumin induces apoptosis via inhibition of PI3-kinase/AKT pathway in acute T cell leukemias. Apoptosis, 2006; 11: 245-254
[43]Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev, 2004; 18: 1926-1945
[44]Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell, 2000; 103: 253-262
[45] Xu Q, Simpson SE, Schalla TJ, et al. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood, 2003; 102: 972-980
[46] Recher C, Beyne-Rauzy O, Demur C, et al. Antileukemic activity or fapamycin in acute myeloid leukemia. Blood, 2005; 105: 2527-2534
[47] Li P, Nijhawan D, Srinivasula SM, et al. Cytochrome C and dATP-dependent formation of Apaf1/caspase-9 complex initiates apoptotic protease cascade. Cell, 1997; 91: 479
[48] Peso LM, Gonzales-Garcia C, Page R, et al. Interleukin-3-induced phosphorylation of Bad through the protein kinase AKT. Science, 1997, 278: 687-689
[49]陈丹英,舒红兵,翟中和等.细胞凋亡与NF-κB激活的信号传导研究.北京大学学报(自然科学版), 2006; 42: 141-146
[50] Madrid LV, Mayo MW, Reuther JY, et al. Akt stimulates the transactivation potential of the Rel/p65 subunit of NF kappa B through utilization of the I kappa B kinase and activation of the mitogen activated protein kinase p38. Biol Chem, 2001; 276: 18934-18940
[51] Cross DA, Culbert AA, Chalmers KA, et al. Selective small-molecule inhibitors of glycogen synthase kinase 23 activity protect primary neurons from death. J Neurochem, 2001; 77: 94-102
[52] Rane MJ, Coxon PY, Powell DW, et al. P38 kinase-dependent MAPK APK-2activation functions as 3-phosphoinositide-dependent kinase-2 for AKT in human neutrophils. J Biol Chem, 2001; 276: 3517-3523
[53] Stellman LS, Pohnert SC, Shelton JG, et al. JAK/STAT, Raf/MEK/ERK, PI3K/AKT and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia, 18: 189-218
1.陈赛娟,陈丽娟,周光飚.白血病基因产物靶向治疗的基础和临床研究.中国实验血液学杂志,2005;13:1-8
2.Kantarjian HM, Cortes JE, O Brien S, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase myeloid leukemia after failure of intereron alpha. Blood, 2004, 104:1979-1988
3.Kaufmann SH, Steensma DP. On the TRAIL of a new therapy for leukemia. Leukemia, 2005, 19:2195-2202
4.郝坡,刘北忠.白血病分子靶向治疗研究进展.现代肿瘤医学. 2007, 15: 719-722
5.金洁.急性髓系白血病的治疗策略.国际输血及血液学杂志. 2007, 30: 198-203
6.Deiniger M W, Goldman JM, Melo JV, et al. The molecular biology of chronic myeloid leukemia. Blood. 2000, 96: 3343-3356
7.Sciandrello G, Garadonna F, Mauro M, et al. Arsenic induced DNA hypomethylation affects chromosomed instability in mammalian cells. Carcinogenesis, 2004, 25: 413-417
8.Lopes deMenezes DE, Jing Peng, Garrett EN, et all. Chir258: a potent inhibitor of FLT-3 kinase in experimental tumor xenograft models of human acute myelogenous leumemia. Clin Cancer Res, 2005, 11: 5281-5291
9.邓扬嘉,娄世锋.白血病靶向治疗新进展.医学综述, 2006,12:116-119
10. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antianglogenesis, involvement of vascular endothelial growh fator. Nat Med, 2002, 8: 128-135
11. Sternberg DW, Gilliland DG. The role of signal transducer and activator of transcription factors in leukemogenesis. J Clin Oncol, 2004, 22: 361-371
12.王东海,王建祥. PI-3K/AKT信号通路异常与白血病.国际输血及血液学杂志,2006, 29: 21-23
13. Loh ML, Vattikuti S, Schubbert S, et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood, 2004, 103: 2325-2331
14.姚尔固.白血病的靶向治疗.白血病·淋巴瘤,2005, 14: 41-43
15. Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously therapy chronic lymphocytic leukemia. Clinical Oncology, 1997, 15: 1567.
16. Jurcic JG, DeBlasio A, Dumont L, et al. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute myeloid leudemia. Clin Cancer Res, 2000, 6: 372-380.
17. Leopold LH, Berger MS, Feingold J. Acute and long-term toxicties associated with gemtuzumab ozogamicin (Mylotarg) therapy of acute myeloid leukemia. Clin Lymphoma, 2002, 2: 21-34.
18. Abken H, Hombach A, Reinhold U, et al. Can combined cell and antibody based immunotherapy outsmart tumor cell. Immunal today, 1998, 19: 2.
19.崔福德..药剂学.北京:人民卫生出版社. 2003
20.杨东光.慢性粒细胞白血病靶向治疗药物实验研究进展.中国实验血液学杂志, 2007, 15: 211-214
21.Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell, 2005; 7:129-141
22. Christman JK. 5-Azacytidine and 5-aza-2-deoxycytidine as inhibitors of DNA methylation; mechanistic studies and their implications for cancer therapy. Oncogene, 2002, 21:5483-5495.
23.Voorhees PM, Dees EC, o’Neil B, et al. The proteasome as a target for cancer therapy, Clinical Cancer, 2003, 9: 6316-6325